Correlation Between CRISPR Therapeutics and Moodys

Can any of the company-specific risk be diversified away by investing in both CRISPR Therapeutics and Moodys at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CRISPR Therapeutics and Moodys into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CRISPR Therapeutics AG and Moodys, you can compare the effects of market volatilities on CRISPR Therapeutics and Moodys and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CRISPR Therapeutics with a short position of Moodys. Check out your portfolio center. Please also check ongoing floating volatility patterns of CRISPR Therapeutics and Moodys.

Diversification Opportunities for CRISPR Therapeutics and Moodys

0.04

Correlation Coefficient

CRISPR Therapeutics  Moodys

Significant diversification

The 3 months correlation between CRISPR and Moodys is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding CRISPR Therapeutics AG and Moodys in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moodys and CRISPR Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CRISPR Therapeutics AG are associated (or correlated) with Moodys. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moodys has no effect on the direction of CRISPR Therapeutics i.e., CRISPR Therapeutics and Moodys go up and down completely randomly.

Pair Corralation between CRISPR Therapeutics and Moodys

Assuming the 90 days trading horizon CRISPR Therapeutics AG is expected to generate 3.05 times more return on investment than Moodys. However, CRISPR Therapeutics is 3.05 times more volatile than Moodys. It trades about 0.13 of its potential returns per unit of risk. Moodys is currently generating about 0.13 per unit of risk. If you would invest  4,080  in CRISPR Therapeutics AG on April 24, 2025 and sell it today you would earn a total of  1,470  from holding CRISPR Therapeutics AG or generate 36.03% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.44%
Values	Daily Returns

CRISPR Therapeutics AG  vs.  Moodys

CRISPR Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, CRISPR Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Moodys

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Moodys are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Moodys reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with CRISPR Therapeutics and Moodys

The main advantage of trading using opposite CRISPR Therapeutics and Moodys positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CRISPR Therapeutics position performs unexpectedly, Moodys can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moodys will offset losses from the drop in Moodys' long position.

The idea behind CRISPR Therapeutics AG and Moodys pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.